Jeremy Tabak
Pulmonary Disease · Miami, FLNPI 1609862515
Payments from drug & device makers
Across 418 payments — averaging $130.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$32K
- Inspire Medical Systems, Inc.$15K
- AstraZeneca$2K
- GSK$2K
- Insmed, Inc.$464
- Sanofi$438
- plus $2K from 26 others
What the payments were for
- Food & beverage$9,04999%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 59 | $32,024 |
| Inspire Medical Systems, Inc. | 28 | $14,895 |
| AstraZeneca | 81 | $2,472 |
| GSK | 124 | $2,216 |
| Insmed, Inc. | 21 | $464 |
| Sanofi | 14 | $438 |
| Philips North America LLC | 15 | $280 |
| Amgen | 12 | $277 |
| Genentech USA, Inc. | 17 | $263 |
| Fisher & Paykel Healthcare Inc | 7 | $212 |
| Mylan Specialty L.p. | 6 | $130 |
| Sunovion Pharmaceuticals Inc. | 5 | $109 |
| Verona Pharma, Inc. | 3 | $81 |
| Mallinckrodt Hospital Products Inc. | 4 | $79 |
| Baxter Healthcare | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Itamar Medical Inc | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Merck | 1 | $13 |
| CMP Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$707
- Inspire$282
- BREZTRI$227
- Inspire Upper Airway Stimulation System$137
- AIRSUPRA$133
- DUPIXENT$114
- NUCALA$113
- BEVESPI AEROSPHERE$102
How this compares
$54,359 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $390,096 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 329 | $276,457 |
| TezspireTezepelumab-Ekko | 20 | $84,304 |
| Breo ElliptaFluticasone/Vilanterol | 168 | $82,662 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $66,048 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $53,027 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $39,284 |
| SymbicortBudesonide/Formoterol Fumarate | 123 | $34,289 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $30,860 |
| Spiriva HandihalerTiotropium Bromide | 32 | $23,940 |
| Pirfenidone | 28 | $22,475 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,912 |
| BreynaBudesonide/Formoterol Fumarate | 31 | $8,731 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 38 | $7,881 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $6,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,216 | $456,027674 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $32,024 | $452,036132 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,472 | $162,553211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- James KrainsonMiami$11.7M
- Lourdes BoschMiami$4.2M
- Manuel SuarezMiami$3M
- Eduardo VasquezMiami$1.9M
- Manuel Hernandez-AbrilMiami$1.9M
- Jaime AvecillasMiami$1.6M
- Trishul SiddharthanMiami$1.2M
- Shirin ShafazandMiami$969K
- Yoel BritoMiami$802K
- Maria Tupayachi OrtizMiami$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.